Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
Vivos Inc. (OTCQB: RDGL) plans two new production sites to diversify manufacturing for its RadioGel® and IsoPet® therapies, targeting one U.S. facility and one international site operational in 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vivos Inc. (OTCQB: RDGL) plans two new production sites to diversify manufacturing for its RadioGel® and IsoPet® therapies, targeting one U.S. facility and one international site operational in 2026.
The company signed a production-space contract at APEL in Richland, Washington; equipment has been ordered, installation is underway, and licensing applications have been submitted. Vivos will continue with its current Texas contract manufacturer through Q2 2026 while pursuing talks with radiopharmaceutical producers in India to reduce shipping costs and expand global access.
Positive
- Signed production-space contract at APEL in Richland, Washington
- Manufacturing equipment ordered and installation underway for automated production
- Target: two facilities (one U.S., one international) planned to be operational in 2026
- International footprint aimed to reduce shipping costs and expand market access
Negative
- Licensing applications submitted; regulatory approval still pending
- Current contract manufacturing continues through Q2 2026, delaying full internal control
- International production talks in India are ongoing and not finalized
Details
News Market Reaction – RDGL
On Feb 17, the day this news came out, RDGL closed 1.67% below the previous close.
Data tracked by StockTitan Argus for the Feb 17 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel® Radionuclide Therapy™ (PRnT™) is preparing to open two new production facilities.
Previous corporate filings have included risk factors regarding the Company’s continued use of a single production site. For the past two years, the Company has been assessing alternate facilities. The Company’s strategic target is to have one domestic production facility, in which the Company will be the manufacturer of record, and one international production facility operational in 2026. These facilities will produce the Y-90 phosphate particles and mix with sterile hydrogel to produce individual patient doses. The Company will continue production with its existing contract manufacturer in Texas through Q2 of 2026.
Vivos has signed a contract for production space at the Applied Process Engineering Laboratory (APEL) in Richland, Washington. Manufacturing equipment has been ordered, installation is underway, and required licensing applications have been submitted. This facility will be the cornerstone of the Company’s future automated production development, positioning Vivos to support higher production volumes, improved efficiency, and long-term expansion. APEL will also serve as a production site for the Company’s Peltier and Duncan Chillers.
In parallel, the Company is engaged in discussions with experienced radiopharmaceutical contract manufacturers in India regarding the establishment of an international production facility. The Company anticipates that one of these facilities could be operational by the end of 2026. An international production footprint is expected to significantly reduce shipping costs and logistical complexity, expanding access to international markets and supporting the global growth of RadioGel® (human) and IsoPet® (veterinary) therapies.
CONTACTS:
| Mike Korenko, ScD | Brad Weeks |
| CEO, Vivos Inc | President, Vivos Inc |
| mkorenko@radiogel.com | Brad.Weeks@vivosinc.com |
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
About Vivos Inc.
Vivos Inc. is a clinical-stage medical device company developing RadioGel®, a precision radiotherapy hydrogel for human and veterinary oncology applications. IsoPet® is commercially available for veterinary use in certified clinics nationwide.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks are detailed in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.